Seagen Highlighted German Hodgkin Study Group Presents P-III Trial (HD21) Results of Adcetris (brentuximab vedotin) for Advanced Classical Hodgkin Lymphoma
Shots:
- The P-III trial (HD21) evaluating Adcetris + CT (BrECADD) vs eBEACOPP in a ratio (1:1) in 1500 patients across 9 countries. The trial conducted by the German Hodgkin Study Group
- The trial met its co-1EPs of non-inferior efficacy & superior tolerability over a highly efficacious yet CT-intense treatment regimen of escalated BEACOPP. In an intent-to-treat analysis @40mos., unprecedented 3yr. PFS (94.9% vs 92.3%), 1yr. PFS (97.5% for BrECADD), 3yr. OS was 98.5% in both treatment arms
- The 12mos. post-treatment safety data were consistent with previously presented HD21 data results, rate of grade ≥2 peripheral neuropathy (1.9% vs 2.7%) with most patients having no or low (grade 1) peripheral neuropathy (98.1% vs 97.3%)
Ref: Businesswire | Image: Seagen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
